13.2K
Downloads
63
Episodes
The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more
Episodes
4 days ago
4 days ago
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Gilead inks deal with generics manufacturers to expand HIV drug access
The bad — J&J announces layoffs at New Brunswick headquarters
The ugly — Amgen sued for hiding $10.7B tax bill
Monday Sep 30, 2024
Monday Sep 30, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good —FDA approves BMS schizophrenia drug
The bad — bluebird bio announces layoffs
The ugly —J&J talc subsidiary files for bankruptcy
Thursday Sep 26, 2024
Thursday Sep 26, 2024
Join senior editor Andrea Corona and Sam Clark, CEO and founder of Terran Biosciences, for a discussion on KarXT's landmark approval, schizophrenia treatment barriers, prodrugs, and more.
Extended Release is an Off Script series that allows us to revisit conversations with our sources to explore new developments, gain deeper insights, and provide updates on the impact of their work. Each episode goes beyond the initial story, offering a richer understanding of key topics and ongoing innovations in the pharma industry.
Monday Sep 23, 2024
Monday Sep 23, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Novo Nordisk shares phase 2a trial data for obesity treatment
The bad — Achilles Therapeutics to discontinue TIL-based therapy
The ugly — Express Scripts files lawsuit against FTC
Thursday Sep 19, 2024
[Solutions Spotlight] Optimizing contamination control in pharma facilities
Thursday Sep 19, 2024
Thursday Sep 19, 2024
Drugmakers face stringent regulations to ensure that products remain free from contaminants that could compromise safety and efficacy. Effective contamination control requires meticulous monitoring of environmental conditions, rigorous testing of products, and implementation of robust cleaning and sterilization procedures.
To better understand these challenges, we sat down with Emily Alkandry, analytical services and quality control manager and Gabrielle Wilson, sterility assurance program manager at Saint-Gobain Life Sciences about the importance of comprehensive contamination control strategies for ensuring product quality and regulatory compliance.
Learn more about Saint-Gobain Life Sciences: https://www.lifesciences.saint-gobain.com/
Monday Sep 16, 2024
Monday Sep 16, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Roche snags FDA nod for subcutaneous cancer immunotherapy
The bad — Moderna to cut R&D expenses by $1.1B
The ugly — Teva reaches $80M opioid settlement with Baltimore
Monday Sep 09, 2024
Monday Sep 09, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Pfizer, Valneva share phase 2 positive Lyme vax data
The bad — IN8bio axes workforce, halts trial
The ugly — AstraZeneca employees detained in China
Tuesday Sep 03, 2024
Tuesday Sep 03, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — FDA approves Illumina cancer biomarker test
The bad — BioMarin reveals more layoffs
The ugly — FDA hits API maker Global Calcium with 483
Wednesday Aug 28, 2024
Pharma’s new age of longevity
Wednesday Aug 28, 2024
Wednesday Aug 28, 2024
The concept of healthspan has recently gained new attention in the pharma industry and rightfully so, given the surprisingly large chasm in the U.S. between average years lived (77.5) and average years lived in good health (63.9). Facing a growing demographic of unhealthy seniors, a handful of innovative biotechs are reframing the longevity discussion: Rather than treat the symptoms of aging one disease at a time, what if we could instead focus on the root causes, enabling treatment of multiple chronic diseases simultaneously?
During this podcast, Chief Content Director Karen Langhauser will share a summary of our most recent cover story, discussing the compelling new research and novel genetic medicines that may help close the gap between healthspan and lifespan.
Monday Aug 26, 2024
Monday Aug 26, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Emergent donates 50,000 doses of mpox vaccine to Africa
The bad — FDA rejects Regeneron blood cancer bispecific antibody
The ugly — China indicts Astellas exec for espionage